Jane Ruppel

1.0k total citations
19 papers, 633 citations indexed

About

Jane Ruppel is a scholar working on Immunology, Oncology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Jane Ruppel has authored 19 papers receiving a total of 633 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Immunology, 9 papers in Oncology and 9 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Jane Ruppel's work include Monoclonal and Polyclonal Antibodies Research (8 papers), Biosimilars and Bioanalytical Methods (6 papers) and Cancer Immunotherapy and Biomarkers (5 papers). Jane Ruppel is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (8 papers), Biosimilars and Bioanalytical Methods (6 papers) and Cancer Immunotherapy and Biomarkers (5 papers). Jane Ruppel collaborates with scholars based in United States, Switzerland and France. Jane Ruppel's co-authors include René Bruno, Tim E. Hotaling, Craig B Struble, Judith A. Fox, Darcy Bates, Sandhya Girish, Daniel C. Adelman, JOHN V. FAHY, John Q. Su and Louis‐Philippe Boulet and has published in prestigious journals such as Proceedings of the National Academy of Sciences, SHILAP Revista de lepidopterología and Analytical Chemistry.

In The Last Decade

Jane Ruppel

18 papers receiving 602 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jane Ruppel United States 13 224 221 162 148 145 19 633
Franklin Schlerman United States 11 77 0.3× 186 0.8× 105 0.6× 101 0.7× 94 0.6× 16 527
Peter Jindra United States 14 97 0.4× 351 1.6× 214 1.3× 22 0.1× 67 0.5× 39 966
Viktoria Rumjantseva United States 7 60 0.3× 141 0.6× 233 1.4× 33 0.2× 98 0.7× 9 805
Chang Shu Wang Canada 12 241 1.1× 37 0.2× 139 0.9× 39 0.3× 173 1.2× 15 565
Yoichi Hamai Japan 21 359 1.6× 122 0.6× 376 2.3× 31 0.2× 646 4.5× 95 1.3k
Shou Ching Tang Canada 6 200 0.9× 103 0.5× 100 0.6× 21 0.1× 66 0.5× 7 506
Kristen N. Cordova United States 4 85 0.4× 206 0.9× 153 0.9× 17 0.1× 75 0.5× 5 413
Brian J. Capaldo United States 11 89 0.4× 140 0.6× 155 1.0× 122 0.8× 104 0.7× 26 439
Stephanie Roberson United States 6 263 1.2× 394 1.8× 113 0.7× 30 0.2× 34 0.2× 10 626
Yoshitaka Kinoshita Japan 8 78 0.3× 130 0.6× 130 0.8× 27 0.2× 65 0.4× 33 425

Countries citing papers authored by Jane Ruppel

Since Specialization
Citations

This map shows the geographic impact of Jane Ruppel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jane Ruppel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jane Ruppel more than expected).

Fields of papers citing papers by Jane Ruppel

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jane Ruppel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jane Ruppel. The network helps show where Jane Ruppel may publish in the future.

Co-authorship network of co-authors of Jane Ruppel

This figure shows the co-authorship network connecting the top 25 collaborators of Jane Ruppel. A scholar is included among the top collaborators of Jane Ruppel based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jane Ruppel. Jane Ruppel is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

19 of 19 papers shown
1.
Ruppel, Jane, et al.. (2025). Atezolizumab neutralizing assay development: a novel way of evaluating assay cutpoint after sample pretreatment. SHILAP Revista de lepidopterología. 11(1).
2.
Hammer, Christian, Jane Ruppel, Lynn Kamen, et al.. (2022). Allelic variation in HLA‐DRB1 is associated with development of a ntidrug antibodies in cancer patients treated with atezolizumab that are neutralizing in vitro. Clinical and Translational Science. 15(6). 1393–1399. 8 indexed citations
3.
Wu, Benjamin, Priya Agarwal, Julia Suchomel, et al.. (2021). Evaluation of atezolizumab immunogenicity: Clinical pharmacology (part 1). Clinical and Translational Science. 15(1). 130–140. 39 indexed citations
4.
Peters, Solange, Peter R. Galle, Coen Bernaards, et al.. (2021). Evaluation of atezolizumab immunogenicity: Efficacy and safety (Part 2). Clinical and Translational Science. 15(1). 141–157. 19 indexed citations
5.
Lowe, Christopher J., Shilpi Mahajan, Mike Reichelt, et al.. (2020). Enrichment of circulating tumor-derived extracellular vesicles from human plasma. Journal of Immunological Methods. 490. 112936–112936. 27 indexed citations
6.
7.
Itatani, Yoshiro, Takamasa Yamamoto, Cuiling Zhong, et al.. (2020). Suppressing neutrophil-dependent angiogenesis abrogates resistance to anti-VEGF antibody in a genetic model of colorectal cancer. Proceedings of the National Academy of Sciences. 117(35). 21598–21608. 68 indexed citations
8.
Shemesh, Colby S., Pascal Chanu, Kris M. Jamsen, et al.. (2019). Population pharmacokinetics, exposure-safety, and immunogenicity of atezolizumab in pediatric and young adult patients with cancer. Journal for ImmunoTherapy of Cancer. 7(1). 314–314. 36 indexed citations
9.
Ruppel, Jane, et al.. (2016). Preexisting Antibodies to an F(ab′)2Antibody Therapeutic and Novel Method for Immunogenicity Assessment. Journal of Immunology Research. 2016. 1–8. 6 indexed citations
10.
Stroh, Mark, Helen Winter, Mathilde Marchand, et al.. (2016). Clinical Pharmacokinetics and Pharmacodynamics of Atezolizumab in Metastatic Urothelial Carcinoma. Clinical Pharmacology & Therapeutics. 102(2). 305–312. 116 indexed citations
11.
Couch, Jessica A., Gu Zhang, Joseph C. Beyer, et al.. (2015). Balancing Efficacy and Safety of an Anti-DLL4 Antibody through Pharmacokinetic Modulation. Clinical Cancer Research. 22(6). 1469–1479. 20 indexed citations
12.
Cereb, Nezih, Jane Ruppel, Julia Pingel, et al.. (2015). Detection of 549 new HLA alleles in potential stem cell donors from the United States, Poland and Germany. HLA. 87(1). 31–35. 13 indexed citations
13.
Sukumaran, Shawgi, Mahrukh Huseni, Jane Ruppel, et al.. (2014). 209 Pre-clinical and translational pharmacology, pharmacokinetics and pharmacodynamics for a humanized anti-OX40 antibody MOXR0916, a T-cell agonist in the treatment of solid tumors. European Journal of Cancer. 50. 71–71. 1 indexed citations
14.
Cereb, Nezih, Jane Ruppel, Julia Pingel, et al.. (2014). Three hundred and seventy‐two novel HLA class II alleles identified in potential hematopoietic stem cell donors from Germany, the United States, and Poland. Tissue Antigens. 84(5). 497–502. 5 indexed citations
15.
Prell, Rodney A., Wendy Halpern, Joseph C. Beyer, et al.. (2014). 424 Nonclinical safety assessment of a humanized anti-OX40 agonist antibody, MOXR0916. European Journal of Cancer. 50. 136–136. 1 indexed citations
16.
Carrasco‐Triguero, Montserrat, et al.. (2012). Overcoming Soluble Target Interference in An Anti-Therapeutic Antibody Screening Assay For An Antibody–Drug Conjugate Therapeutic. Bioanalysis. 4(16). 2013–2026. 26 indexed citations
17.
FAHY, JOHN V., Donald W. Cockcroft, Louis‐Philippe Boulet, et al.. (1999). Effect of Aerosolized Anti-IgE (E25) on Airway Responses to Inhaled Allergen in Asthmatic Subjects. American Journal of Respiratory and Critical Care Medicine. 160(3). 1023–1027. 121 indexed citations
18.
Liu, Jim, Jane Ruppel, & Steven J. Shire. (1997). Interaction of Human IgE with Soluble Forms of IgE High Affinity Receptors. Pharmaceutical Research. 14(10). 1388–1393. 18 indexed citations
19.
Fox, Judith A., et al.. (1996). Tissue distribution and complex formation with IgE of an anti-IgE antibody after intravenous administration in cynomolgus monkeys.. Journal of Pharmacology and Experimental Therapeutics. 279(2). 1000–1008. 95 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Franklin Schlerman Breakdown of academic impact, for papers by Peter Jindra Breakdown of academic impact, for papers by Viktoria Rumjantseva Breakdown of academic impact, for papers by Chang Shu Wang Breakdown of academic impact, for papers by Yoichi Hamai Breakdown of academic impact, for papers by Shou Ching Tang Breakdown of academic impact, for papers by Kristen N. Cordova Breakdown of academic impact, for papers by Brian J. Capaldo Breakdown of academic impact, for papers by Stephanie Roberson Breakdown of academic impact, for papers by Yoshitaka Kinoshita
Rankless by CCL
2026